Definiens and BioImage Announce Collaboration for High-Content Screening (HCS) Applications
Munich and Copenhagen. Definiens, a leading provider of advanced image analysis solutions, and BioImage, a leading drug discovery and assay services company announced a worldwide, non-exclusive co-development and marketing agreement to deliver tailored applications to the high-content screening (HCS) market.
Definiens' and BioImage's offerings are complementary, whereby BioImage is providing cell-based pathway screening assays with its unique Redistribution® technology, and Definiens is providing Definiens Cellenger®, their unique software for automated image analysis, based on Cognition Technology.
The agreement also includes co-development efforts, combining BioImage's high content assay expertise with Definiens' unique image analysis solution, aiming at the development of specific applications in the area of HCS.
This powerful combination enables customers to perform robust data extraction from high content cell-based assays with a flexibility and a throughput not previously available. BioImage's Redistribution® technology aims at discovering new generations of small molecule drugs that change the activity of signalling pathways by modulating protein translocation. In addition to drug targets such as kinases, Redistribution® assays address disease targets that are not amenable to traditional drug discovery. BioImage performs pathway screens involving protein translocation read-outs using their high content Redistribution® platform. BioImage uses Definiens Cellenger® to measure and quantify the activity of small molecules in Redistribution assays.
The Definiens Cellenger® HCS solution is an advanced software system for the powerful automated high-content analysis of cell-based assays that enable the reliable and fully automated data extraction. The Cellenger® HCS solution allows detailed analysis of structures of interest even in complex image data and the extracted objects are counted and morphometrically measured.
"Our partnership with BioImage brings important benefits to our customers," said Thomas Heydler, CEO of Definiens AG. "With our leading-edge Cellenger HCS solution we offer a comprehensive application for automated image analysis in the HCS marketplace. Now, with the support of BioImage's expertise in developing specific applications for high-content screening, we provide even more sophisticated capabilities. Partnering with companies such as BioImage will continue to enhance Definiens' leadership role in image analysis for the high-content screening market."
"Combining forces is the right way to meet today's demand of bringing together the best combination of technologies for leveraging the potential of high content cell-based assays" added Dr Patrik Dahlen, CEO of BioImage. "Our collaboration with Definiens significantly enhances our technological capabilities, and allows us to make image analysis an integral part of assay development. Cell-based screening will reach a new form of excellence by this joint effort. We are looking forward to make this collaboration a real success story in the future."
Commercial terms of the collaboration were not disclosed.
Other news from the department business & finance
These products might interest you
Limsophy by AAC Infotray
Optimise your laboratory processes with Limsophy LIMS
Seamless integration and process optimisation in laboratory data management
ERP-Software GUS-OS Suite by GUS
Holistic ERP solution for companies in the process industry
Integrate all departments for seamless collaboration
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.
